Tag: CytoReason

[CytoReason in Israel Hayom] Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development

CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership with Helixrus, a Korean company focused on biological big data and multi-omics, the company announced Tuesday. The partnership will see Helixrus represent CytoReason’s unique artificial intelligence (AI) platform and professional services in the Korean market. Read...

Read More

[CytoReason in Share Talk] Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason

24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason , a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples. Read...

Read More